u/mateusz_mensah

Has this been raised with whoever prescribes?

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Same. Perimenopause overlapping with all of this is the least documented area on the whole site.

Which programme and which readout are you quoting?

Are you comparing against phase 3 numbers for something else? They are not comparable.

Resolution between two peaks depends on retention, selectivity and efficiency. A shallower gradient buys retention and usually resolution, at the cost of peak width and run time.

Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.

the boards keep comparing it to injectables at matched doses, which is meaningless

Are you tracking heart rate at all?

What is the source for that figure — the published paper or a summary of it?

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Left up and added to the vendor source page log.

This is why the template has a batch field. Without it the result is about a vial nobody can identify.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

That is a general statement about gastric emptying, and the question was about a specific product.

What was the claim on the certificate you are comparing against?

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

a blank injection between samples costs four minutes and settles most arguments

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

reproducibility beats resolution if you only get one of them

iron and ferritin questions come up here more than anywhere else on the site

Brought the cycle-annotated log to an appointment and it changed the conversation completely.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

How many separate lots does your series cover?

Adding the boring but useful bit: say whether you paid for it. It is the basis of the whole log.

I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.

Is that the 48-week figure or an earlier readout?

The thing that surprised me was how much of the discussion here is inference rather than measurement.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

vendor, compound, batch, service, result — that is the template

the tolerability profile reads broadly similar to the class

chidi_yilmaz is right that milligram comparisons across classes tell you nothing.

the column has a history and it shows in the peak shape

a lot of the confident posting here is extrapolation

date of analysis matters as much as the number

post the claim next to the result or the number floats

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.